---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004049"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:04:36.763768+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phathom announces positive Ph3 NERD-301 topline results for vonoprazan; both doses met primary endpoint

## Summary
- Vonoprazan 10 mg and 20 mg both achieved significantly greater 24-hour heartburn-free days vs placebo (46.4% and 46.0% vs 27.5%; p<0.0001).
- Median percentage of heartburn-free days: 48.3% (10 mg), 46.7% (20 mg), 17.0% (placebo).
- Safety profile comparable to placebo; most common AE was nausea (2.3% 10 mg, 3.1% 20 mg, 0.4% placebo).
- Blinded 20-week long-term extension ongoing; full results expected later in 2023.
- Discussions with FDA ongoing regarding separate Phase 3 trial for on-demand dosing in NERD.

## SEC filing metadata
- accession: 0001193125-23-004049
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312523004049/0001193125-23-004049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312523004049/d432177d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004049
- JSON: https://secwatch.observer/filing/0001193125-23-004049.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.